CHRONIC SPONTANEOUS URTICARIA

This study tests a drug called remibrutinib in teenagers aged 12 to 17 who have chronic spontaneous urticaria (hives that come and go for no clear reason) that isn't controlled by antihistamines. About 100 participants will receive either the drug or a placebo for 24 weeks, with …

This study tests a new drug called remibrutinib (a tablet) against a placebo in 44 adults with chronic hives (either spontaneous or triggered by things like pressure or cold). The goal is to see if it reduces symptoms like itching and burning, and how it works in the body. Partic…

This study tracks 350 people with chronic spontaneous urticaria (hives) who are starting remibrutinib, a new drug. Researchers will survey patients and their doctors to see how well the drug controls symptoms and how satisfied patients are. The goal is to understand real-world ef…

This study follows about 3,280 adults with chronic spontaneous urticaria (CSU) to see how well remibrutinib controls their hives in everyday medical practice. Participants either continue standard antihistamines or switch to remibrutinib, and researchers track symptom control and…

This study tests a new drug called lesigercept in 150 adults with chronic spontaneous urticaria (hives lasting 6+ months) that aren't controlled by standard antihistamines. Participants receive either lesigercept or a placebo injection. The main goal is to see if lesigercept redu…

This Phase 2 trial tests an injectable biologic called CM512 in 48 adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with standard antihistamines. Participants are randomly assigned to receive either CM512 or a placebo shot, an…

This study tests an experimental drug called BLU-808 for people with chronic hives (urticaria) that don't get better with standard antihistamines. The drug works by blocking a protein called KIT, which may help control the allergic reaction causing the hives. About 105 adults wil…

This study follows about 500 adults with chronic spontaneous urticaria (CSU) who are either starting remibrutinib or sticking with standard antihistamines. Researchers will track how well the drug controls hives and itching over 24 months, and monitor for side effects. The goal i…

This program provides remibrutinib, an experimental drug, to adults with chronic spontaneous urticaria (long-term hives) that haven't improved with antihistamines or omalizumab. Participants take the drug as prescribed to help control their symptoms. The goal is to offer access t…

This study looks at whether people with chronic spontaneous urticaria (long-term hives) who are well-controlled on omalizumab every 4 weeks can switch to every 6 weeks without losing control. Forty adults will be randomly assigned to continue standard dosing or extend their injec…

This study tests an experimental daily pill, ritlecitinib, for adults with chronic spontaneous urticaria (long-term itchy hives and swelling) that antihistamines don't fully control. About 200 participants will receive either 50 mg, 100 mg, or a placebo for 12 weeks, then all wil…

This study tests a new daily pill (remibrutinib) against a standard injected drug (dupilumab) for adults with chronic hives that antihistamines can't control. About 400 participants will take either the pill or get the shot for 4 weeks to see which works faster. The goal is to re…

This study tests a new medication called ARS-2 for people with chronic spontaneous urticaria (long-term hives). It aims to see if ARS-2 can quickly reduce itching and hives during flare-ups. The trial involves 42 adults who will receive either ARS-2 or a placebo during separate f…

This early-stage trial tests the safety of an experimental oral drug called EDP-978 in 98 healthy adults. Researchers will give single and multiple doses to see how the body handles it and whether it causes side effects. The drug is being developed for chronic hives, but this stu…

This study watches 400 people with chronic spontaneous urticaria (long-lasting hives) who are prescribed dupilumab by their doctor. Researchers collect information from medical records and patient surveys to see how the drug works in real life, its safety, and how it affects qual…

This study aims to find biological markers (biomarkers) that can help diagnose and monitor chronic induced urticaria (CIndU), a condition where specific triggers like cold or pressure cause itchy hives or swelling. Researchers will compare 40 participants—including people with CI…